Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.